软骨肉瘤的表观遗传学研究进展
Advances in Epigenetics of Chondrosarcoma
李超 1浦飞飞 2刘建湘1
作者信息
- 1. 华中科技大学同济医学院附属协和医院骨科,武汉 430022
- 2. 华中科技大学同济医学院附属武汉中西医结合医院骨科,武汉 430022
- 折叠
摘要
软骨肉瘤是第二常见的原发性恶性骨肿瘤,其治疗效果差,易复发和转移,对放化疗均不敏感,治疗方式在过去30～40年间停滞不前,还是以手术切除为主.对于软骨肉瘤的发生发展机制研究仍未完全明确,亦无特效药物.因此,探寻软骨肉瘤新的发生发展机制,从而寻找新的治疗方法和药物靶点,对临床治疗具有重大意义.有研究发现表观遗传学在软骨肉瘤发生发展中有重要作用.表观遗传学是指DNA序列未发生变化,但生物体的表型发生了可遗传性的改变,其机制主要包括DNA甲基化、非编码RNA调控、组蛋白修饰、染色质重塑等.该文就目前表观遗传学在软骨肉瘤中的研究进展做一综述,为进一步深入软骨肉瘤的研究,寻找新的治疗靶点提供方向.
Abstract
Chondrosarcoma(CHS)is the second most common primary bone malignancy in human.Recurrence and metasta-sis are common among patients,and the efficacies of radiotherapy and chemotherapy are limited.The development of CHS treat-ment method has stagnated in the past 30-40 years,and surgical treatment is still the dominant option.Research on the patho-genesis mechanism of CHS is still not clear,and there is no specific drug.Therefore,it is of great significance to explore the pathogenesis of CHS,so as to find new treatment methods and drug targets for clinical treatment.Some studies have shown that epigenetic factor play an important role in the pathogenesis of CHS.Epigenetics refers to changes in the expression level and function of a gene without the change in its DNA sequence,leading to a heritable phenotype.The mechanisms of epigenetics mainly include DNA methylation,non-coding RNA regulation,histone modification,and chromatin remodeling.In this review,the recent progress in the field of epigenetics in CHS is summarized,which provides a direction for further research on CHS and searching for new therapeutic targets.
关键词
软骨肉瘤/表观遗传学/DNA甲基化/非编码RNA/组蛋白修饰Key words
chondrosarcoma/epigenetics/DNA methylation/non-coding RNA/histone modification引用本文复制引用
基金项目
国家自然科学基金资助项目(82072978)
湖北省自然科学基金资助项目(2024AFB1011)
湖北省自然科学基金资助项目(2020CFB861)
出版年
2024
NETL
NSTL
万方数据